Cheviot Value Management LLC decreased its holdings in Becton Dickinson and Co (NYSE:BDX) by 3.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,167 shares of the medical instruments supplier’s stock after selling 630 shares during the period. Becton Dickinson and comprises approximately 2.0% of Cheviot Value Management LLC’s holdings, making the stock its 18th largest holding. Cheviot Value Management LLC’s holdings in Becton Dickinson and were worth $4,113,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in BDX. Ascension Asset Management LLC increased its stake in shares of Becton Dickinson and by 4.2% during the second quarter. Ascension Asset Management LLC now owns 4,970 shares of the medical instruments supplier’s stock valued at $1,191,000 after buying an additional 200 shares during the period. Bfsg LLC increased its stake in shares of Becton Dickinson and by 1.9% during the second quarter. Bfsg LLC now owns 10,515 shares of the medical instruments supplier’s stock valued at $2,519,000 after buying an additional 201 shares during the period. Toth Financial Advisory Corp increased its stake in shares of Becton Dickinson and by 0.8% during the second quarter. Toth Financial Advisory Corp now owns 24,989 shares of the medical instruments supplier’s stock valued at $5,986,000 after buying an additional 203 shares during the period. Chesapeake Wealth Management increased its stake in shares of Becton Dickinson and by 5.5% during the second quarter. Chesapeake Wealth Management now owns 4,179 shares of the medical instruments supplier’s stock valued at $1,001,000 after buying an additional 219 shares during the period. Finally, Hamilton Point Investment Advisors LLC increased its stake in shares of Becton Dickinson and by 0.7% during the second quarter. Hamilton Point Investment Advisors LLC now owns 31,359 shares of the medical instruments supplier’s stock valued at $7,512,000 after buying an additional 230 shares during the period. Institutional investors and hedge funds own 86.73% of the company’s stock.

Several equities analysts have recently commented on the company. ValuEngine upgraded Becton Dickinson and from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Citigroup raised their price target on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. JPMorgan Chase & Co. upgraded Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price target on the stock in a research note on Thursday, June 21st. Royal Bank of Canada restated a “hold” rating and set a $248.00 price target on shares of Becton Dickinson and in a research note on Friday, August 3rd. Finally, KeyCorp restated a “buy” rating and set a $264.00 price target on shares of Becton Dickinson and in a research note on Friday, August 3rd. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Becton Dickinson and presently has an average rating of “Buy” and a consensus price target of $247.71.

Shares of BDX stock opened at $260.32 on Friday. Becton Dickinson and Co has a 1-year low of $191.53 and a 1-year high of $261.11. The stock has a market cap of $68.94 billion, a P/E ratio of 24.68, a P/E/G ratio of 1.76 and a beta of 1.13. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.86 by $0.05. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The company had revenue of $4.28 billion for the quarter, compared to the consensus estimate of $4.25 billion. During the same quarter last year, the company earned $2.46 earnings per share. The firm’s revenue for the quarter was up 41.0% compared to the same quarter last year. equities analysts anticipate that Becton Dickinson and Co will post 11.01 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Investors of record on Friday, September 7th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.15%. The ex-dividend date is Thursday, September 6th. Becton Dickinson and’s payout ratio is currently 31.65%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Recommended Story: Calculate Your Return on Investment (ROI)

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.